Verastem Initiates Trial of Defactinib in Japan

Verastem, Inc. , focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced the initiation of a Phase 1 trial of defactinib , a potent inhibitor of focal adhesion kinase , in Japanese patients with advanced solid tumors.

http://www.businesswire.com/portal/site/topix/index.jsp?ndmViewId=news_view&newsId=20130924005192&newsLang=en&ndmConfigId=1000639&vnsId=41